MediPharm Labs Launches High CBD Wellness Oils in Quebec;
BARRIE, Ontario, May 26, 2021 (GLOBE NEWSWIRE) – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a world leader in the extraction, distillation and pharmaceutical grade cannabis derivative products pharmaceutical, today announced its launch of its first wellness products in Quebec and shipped its first order of premium CBD oils for retail sale to the Société québécoise du cannabis (SQDC), the only legal retailer of the province for cannabis products.
“As our Canadian domestic market begins to recover and the government works to reopen the economy, we remain excited about our growth prospects in Quebec as we launch new products and increase our local presence,” said Keith Strachan, Interim President and CEO, MediPharm Labs. “Quebec, one of the largest consumer markets in Canada, marks our seventh provincial distribution agreement. Thanks to our expanded footprint, we now bring our quality products to 95% of the retail market in Canada.
MediPharm has shipped its first order of its own MediPharm branded CBD oils – CBD 25 Regular Formula and CBD 50 Plus Formula – which will be on sale through the Société québécoise du cannabis retail outlets and e-commerce platform ( SQDC).
In Canada, in addition to Quebec, MediPharm Labs’ cannabis products are available in Ontario, Nova Scotia, Alberta, British Columbia, Manitoba, and Saskatchewan, with more provinces expected to be added as well. 2021.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the production of pharmaceutical grade purified cannabis oil and concentrates and advanced derivative products using a certified good manufacturing practice facility with clean rooms to ISO standards. MediPharm Labs has invested in a team of experts, research-driven, cutting-edge technology, downstream purification methodologies and specially designed facilities with five primary extraction lines for the delivery of pure, reliable and pure cannabis products. precisely dosed for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid products on the market. national and international markets. As a global leader, MediPharm Labs has achieved commercial exports to Australia and fully commercialized its Australian extraction facility. MediPharm Labs Australia was established in 2017.
CAUTION REGARDING FORWARD-LOOKING INFORMATION:
This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this press release. Any statement that involves discussions regarding predictions, expectations, beliefs, plans, projections, goals, assumptions, events or future performance (often but not always using expressions such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “planned”, “plans”, “estimates”, “believes” or ” means ”or variations of such words and expressions or stating that certain actions, events or results“ could ”or“ could ”,“ would ”,“ could ”or“ will ”be supposed to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this press release, forward-looking statements relate to, among other things, the commencement of the recovery of the Company’s domestic Canadian market; growth prospects in Quebec; launch of new products; increased local presence; and distribution to other provinces in 2021. Forward-looking statements are necessarily based on a number of estimates and assumptions which, while believed to be reasonable, are subject to risks, uncertainties and other known and unknown factors that may cause actual results and future events differ materially from those expressed or implied by such forward-looking statements. These factors include, but are not limited to: general uncertainties about business, economy, competition, politics and society; the inability of MediPharm Labs to obtain adequate funding; delay or failure to receive regulatory approvals; and other factors discussed in documents filed by MediPharm Labs, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Therefore, readers should not place undue reliance on any forward-looking statements and information contained in this press release. Except as required by law, MediPharm Labs assumes no obligation to update any forward-looking statements of beliefs, opinions, projections or other factors, as they change.